Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884749 | 0.91 | CHRNA7 (0.41) | CHRNB2CHRNA4CHRNA7ALDH1A1HRH3 | |
| SCHEMBL6882045 | 0.89 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNA7ALDH1A1HRH3 | |
| SCHEMBL6881202 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA7ALDH1A1MEN1 | |
| SCHEMBL6881034 | 0.89 | CHRNA7 (0.40) | CHRNB2CHRNA4CHRNA7ALDH1A1HRH3 | |
| SCHEMBL6881959 | 0.87 | HPGD (0.46) | CHRNB2CHRNA4CHRNA7ALDH1A1HRH3 | |
| SCHEMBL6881009 | 0.86 | SLC6A5 (0.40) | CHRNB2CHRNA4CHRNA7HRH3 | |
| SCHEMBL6883341 | 0.86 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNA7ALDH1A1HRH3 | |
| SCHEMBL7601445 | 0.84 | MAPK14 (0.38) | CHRNB2CHRNA4CHRNA7ALDH1A1MAPK1 | |
| SCHEMBL6884697 | 0.84 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNA7ALDH1A1USP30 | |
| SCHEMBL6883327 | 0.83 | CHRNA7 (0.43) | CHRNB2CHRNA4CHRNA7ALDH1A1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381603-A2 | QUINUCLIDINE-SUBSTITUEDARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-21 | — | — | EP | claimed |
| US-6492386-B2 | TREATING A DISEASE OR CONDITION IN A MAMMAL, WHEREIN THE ALPHA 7 NICOTINIC-ACETYLCHOLINE RECEPTOR IS IMPLICATED | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | claimed |
| US-6486172-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS | PHARMACIA & UPJOHN COMPANY | 2002-11-26 | — | — | US | claimed |
| US-6479510-B2 | N-((2S,3R)-2-METHYL-1-AZABICYCLO(2.2.2)OCT-3-YL)-4-(4-HYDROXYP HENOXY)- BENZAMIDE FOR EXAMPLE; TREATING DISEASES OF THE ALPHA-7-NICOTINIC ACETYLCHOLINE RECEPTOR I.E. SCHIZOPHRENIA, OR PSYCHOSIS | PHARMACIA & UPJOHN COMPANY | 2002-11-12 | — | — | US | claimed |
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | PHARMACIA & UPJOHN COMPANY | 2002-05-02 | — | — | US | claimed |
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-25 | — | — | US | claimed |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-04 | — | — | US | claimed |
| WO-2002016356-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016357-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016358-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1381603-A2 | QUINUCLIDINE-SUBSTITUEDARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6492386-B2 | TREATING A DISEASE OR CONDITION IN A MAMMAL, WHEREIN THE ALPHA 7 NICOTINIC-ACETYLCHOLINE RECEPTOR IS IMPLICATED | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6486172-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS | PHARMACIA & UPJOHN COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-6479510-B2 | N-((2S,3R)-2-METHYL-1-AZABICYCLO(2.2.2)OCT-3-YL)-4-(4-HYDROXYP HENOXY)- BENZAMIDE FOR EXAMPLE; TREATING DISEASES OF THE ALPHA-7-NICOTINIC ACETYLCHOLINE RECEPTOR I.E. SCHIZOPHRENIA, OR PSYCHOSIS | PHARMACIA & UPJOHN COMPANY | 2002-11-12 | — | — | US | disclosed |
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | PHARMACIA & UPJOHN COMPANY | 2002-05-02 | — | — | US | disclosed |
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-25 | — | — | US | disclosed |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2002016356-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016357-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016358-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNB2 595/4885CHRNA4 594/4885CHRNA7 365/4885 |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNB2 595/4885CHRNA4 594/4885CHRNA7 365/4885 |
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | CHRNA7, CHRNA1, CHRNB1 | CHRNB2 14/4885CHRNA4 11/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.